Merck & Company, Inc.
As of Oct 22, 2026, Merck is in Stage 2, the uptrend phase, now in week 16 (since Jul 1, 2026). It closed at $147.24, 5.3% below its 52-week high and above its 200-day average, which is rising.
Merck & Co., Inc. operates as a healthcare company worldwide. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 9 in Drug Manufacturers - General · #1 of 272 in Health Care
Is MRK early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MRK among Drug Manufacturers - General1st of 21 by relative strength
All 21 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | MRK | Stage 2 · wk 16 | 92 | −0.6% |
| 2 | BIIB | Stage 2 · wk 21 | 92 | +11.6% |
| 3 | LLY | Stage 2 · wk 1 | 90 | +13.5% |
| 4 | AMGN | Stage 2 · wk 16 | 87 | +10.1% |
| 5 | OGN | Stage 2 · wk 23 | 87 | +0.1% |
| 6 | BMY | Stage 3 · wk 1 | 85 | +4.1% |
| 7 | JNJ | Stage 2 · wk 16 | 83 | −0.6% |
| 8 | PFE | Stage 2 · wk 8 | 77 | +7.9% |
Merck: quick answers
What stage is Merck in?
As of Oct 22, 2026, Merck (MRK) is in Stage 2, the uptrend phase. It entered Stage 2 on Jul 1, 2026 and is in week 16. What the four stages mean
Is Merck in an uptrend?
Yes. Merck is in a Stage 2 uptrend. It trades 18.3% above its 200-day average, which is rising.
How far is Merck from its 52-week high?
Merck closed at $147.24 on Oct 22, 2026, 5.3% below its 52-week high of $155.53. Its 52-week low is $80.14.
How has Merck performed over the past year?
As of Oct 22, 2026, Merck is up 73.0% over the past year and up 41.2% so far in 2026.
Which sector and industry is Merck in?
Merck is in the Drug Manufacturers - General industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - General
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.